CDK4 and Miyoshi myopathy: In concurrence with this, two phase II trials testing palbociclib in advanced/RR MM (the TAPUR and NCI-MATCH trial) are currently actively recruiting MM patients with an aberrant Cdk4 or cyclin D expression.